EPS for Allergan plc (AGN) Expected At $3.97

October 14, 2018 - By Marguerite Chambers

Allergan plc (NYSE:AGN) LogoInvestors sentiment increased to 2 in 2018 Q2. Its up 1.50, from 0.5 in 2018Q1. It increased, as 2 investors sold Allergan plc shares while 1 reduced holdings. 3 funds opened positions while 3 raised stakes. 69,030 shares or 10.85% less from 77,429 shares in 2018Q1 were reported.
Cubic Asset Mngmt Limited Liability Corp holds 0.1% or 2,130 shares in its portfolio. Whittier Trust Communication owns 2,749 shares for 0.02% of their portfolio. Gemmer Asset Management Ltd Liability holds 117 shares. Mitchell Mcleod Pugh And Williams reported 0.46% of its portfolio in Allergan plc (NYSE:AGN). 15,343 were reported by Callahan Advsr Limited Liability. Grassi Investment Management accumulated 43,335 shares or 1.16% of the stock. Whittier Trust Communication Of Nevada Inc reported 21 shares. Staley Advisers Inc has 1,400 shares for 0.02% of their portfolio.

Analysts expect Allergan plc (NYSE:AGN) to report $3.97 EPS on November, 7.They anticipate $0.18 EPS change or 4.34 % from last quarter’s $4.15 EPS. AGN’s profit would be $1.35B giving it 11.54 P/E if the $3.97 EPS is correct. After having $4.42 EPS previously, Allergan plc’s analysts see -10.18 % EPS growth. The stock increased 0.58% or $1.06 during the last trading session, reaching $183.28. About 2.15 million shares traded or 19.25% up from the average. Allergan plc (NYSE:AGN) has declined 17.68% since October 14, 2017 and is downtrending. It has underperformed by 33.30% the S&P500.

Allergan plc (NYSE:AGN) Ratings Coverage

Among 11 analysts covering Allergan (NYSE:AGN), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Allergan had 16 analyst reports since April 16, 2018 according to SRatingsIntel. The rating was maintained by Mizuho on Monday, June 11 with “Neutral”. Raymond James maintained the stock with “Outperform” rating in Monday, September 17 report. Citigroup maintained Allergan plc (NYSE:AGN) rating on Tuesday, April 24. Citigroup has “Buy” rating and $200 target. Bank of America maintained it with “Buy” rating and $213 target in Tuesday, June 12 report. The rating was maintained by Mizuho with “Hold” on Wednesday, May 30. The firm earned “Buy” rating on Monday, April 16 by Cowen & Co. The firm has “Hold” rating given on Monday, May 7 by Cantor Fitzgerald. The stock of Allergan plc (NYSE:AGN) earned “Neutral” rating by Cantor Fitzgerald on Tuesday, May 1. The stock of Allergan plc (NYSE:AGN) has “Outperform” rating given on Thursday, August 23 by Wells Fargo. As per Thursday, August 23, the company rating was maintained by Morgan Stanley.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $62.21 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women??s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer??s disease.

More notable recent Allergan plc (NYSE:AGN) news were published by: Prnewswire.com which released: “Allergan to Report Third Quarter 2018 Earnings and Host Conference Call and Webcast” on October 01, 2018, also Seekingalpha.com with their article: “FDA OKs Paratek’s sarecycline for acne” published on October 02, 2018, Seekingalpha.com published: “Allergan to acquire Bonti for $195M” on September 14, 2018. More interesting news about Allergan plc (NYSE:AGN) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on October 09, 2018 as well as Benzinga.com‘s news article titled: “JMP: Changing Competitive Landscape Makes Revance Less Appealing” with publication date: September 17, 2018.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News